Ketamine Tablet Dosing Guide

Dosing is the single most important variable in ketamine tablet therapy. Too low, and the drug produces no meaningful therapeutic effect. Too high, and side effects become intolerable or unsafe. The goal of any dosing protocol is to find the minimum effective dose for each individual patient through careful titration — the sweet spot where therapeutic benefit is maximized while side effects remain manageable.

This guide covers the principles, protocols, and practical considerations that govern ketamine tablet dosing for both psychiatric and pain indications. For a broader treatment overview, see the complete guide to ketamine tablets.

Dosing Fundamentals

Weight-Based vs. Fixed Dosing

Ketamine tablet dosing can follow two approaches:

Weight-based dosing calculates the dose relative to body weight (mg/kg). This is the most common approach in clinical practice and accounts for the basic pharmacokinetic reality that larger bodies require more drug to achieve equivalent plasma concentrations.

Fixed dosing uses a set milligram amount regardless of weight. Some protocols, particularly for pain, use fixed low doses (25 mg, 50 mg, or 100 mg) based on the rationale that at low therapeutic levels, the difference between weight-based doses is clinically insignificant.

Most psychiatric protocols use weight-based dosing. Most pain protocols use either approach depending on the clinician's preference and the specific protocol.

The Therapeutic Dose Range

For ketamine tablets, the general therapeutic range is:

These ranges reflect general clinical practice and published protocols. Individual prescribers may use different ranges based on clinical experience and patient-specific factors.

Why Oral Doses Are Higher Than IV Doses

A common source of confusion is why oral doses appear so much higher than IV doses. The standard IV ketamine dose for depression is 0.5 mg/kg — yet oral doses may be 1.0-3.0 mg/kg or even higher.

The explanation is bioavailability. When ketamine is swallowed:

• Only 10-25% reaches systemic circulation as unchanged ketamine
• A 2.0 mg/kg oral dose delivers approximately 0.2-0.5 mg/kg of active ketamine to the bloodstream
• This roughly approximates the plasma levels achieved by a 0.5 mg/kg IV dose, though the kinetic profile differs substantially

Patients should understand that a "high" oral dose in milligrams does not mean they are receiving a dangerously large amount of ketamine. The oral dose compensates for the drug lost to first-pass metabolism.

Titration Protocols

The Standard Titration Approach

Most clinicians follow a stepwise titration approach:

Week 1-2: Starting dose

• Begin at 0.5 mg/kg (or 0.25 mg/kg for cautious starts)
• Dose 2-3 times during the first week
• Assess tolerability: nausea, dissociation intensity, cardiovascular effects
• Assess early response: any change in mood, pain, or target symptoms

Week 3-4: First adjustment

• If tolerability is acceptable but response is insufficient, increase by 0.25-0.5 mg/kg
• If response is present, maintain current dose
• If side effects are problematic, reduce or address the specific issue (anti-nausea medication, timing adjustments)

Week 5-6: Second adjustment

• Further titration if needed
• Most patients are within their therapeutic range by this point
• Consider frequency adjustment rather than dose increase if partial response is present

Week 7+: Maintenance optimization

• Establish the maintenance dose and frequency
• Some patients do well on a lower maintenance dose than the acute treatment dose
• Document the minimum effective dose for future reference

Rapid Titration (Acute Situations)

In cases of severe depression with acute distress, some clinicians use a more aggressive schedule:

• Day 1: 0.5 mg/kg
• Day 3: 0.75 mg/kg (if tolerated and insufficient response)
• Day 5: 1.0 mg/kg (if tolerated and insufficient response)
• Day 7: Reassess and adjust

This approach is used less commonly and requires closer monitoring. It prioritizes rapid identification of the effective dose over gradual accommodation.

Conservative Titration (Sensitive Patients)

For patients who are medication-sensitive, elderly, have low body weight, or have hepatic impairment:

• Start at 0.25 mg/kg or even lower
• Increase by 0.125-0.25 mg/kg per adjustment
• Allow 2-3 weeks between increases
• Accept a lower maximum dose if clinical response is achieved

Depression-Specific Dosing

Acute Treatment Phase

The acute phase for depression typically lasts 2-6 weeks:

Standard protocol:

• 0.5 mg/kg, 2-3 times per week
• Titrate to 1.0-2.0 mg/kg if needed
• Assess with PHQ-9 or similar validated instrument weekly
• A 50% reduction in depression score or a score <10 on PHQ-9 indicates response

Augmentation protocol (added to existing antidepressant):

• Same dosing approach
• Do not discontinue the existing antidepressant during ketamine initiation
• Some clinicians prefer lower starting doses when adding to existing medications

Maintenance Phase

Once an effective dose is established:

• Reduce frequency gradually: from 2-3 times weekly to once weekly, then every 2 weeks
• Some patients maintain response on once-weekly dosing indefinitely
• Others can extend to every 2-3 weeks
• A minority achieve sustained remission and can taper off entirely
• If symptoms return during frequency reduction, increase back to the last effective frequency

Response Assessment

Standardized tools for monitoring depression response:

• PHQ-9: Score <5 suggests remission; decrease of 5+ points is clinically meaningful
• MADRS: Score <10 suggests remission; 50% reduction indicates response
• Clinical Global Impression (CGI): Clinician-rated overall improvement
• Patient self-report: Subjective experience of mood, energy, sleep, motivation

Pain-Specific Dosing

Low-Dose Continuous Protocol

For chronic pain conditions (neuropathic pain, CRPS, fibromyalgia):

• Start at 0.25 mg/kg or a fixed dose of 25-50 mg
• Take 1-3 times daily
• Titrate slowly based on pain relief and tolerability
• Effective doses for pain are often lower than for depression
• Maximum daily doses typically range from 100-300 mg total

Intermittent High-Dose Protocol

Some pain protocols use higher intermittent doses:

• 1.0-2.0 mg/kg, taken 2-3 times per week
• Similar to depression dosing but targeting pain outcomes
• May produce more dissociation than low-dose continuous protocols
• Used when low-dose continuous dosing is insufficient

Palliative Care Dosing

In palliative care, dosing is often more flexible:

• Starting dose of 0.5 mg/kg 2-3 times daily
• Titrate based on pain relief; higher doses may be appropriate given the clinical context
• Concurrent opioid use requires careful monitoring but is common and generally safe at therapeutic doses
• Quality of life considerations may justify higher doses than other clinical contexts

Practical Dosing Considerations

Timing

When to take the dose:

• Evening dosing is preferred by most patients (accommodates sedation, allows recovery during sleep)
• Morning dosing is appropriate for patients who experience insomnia after dosing
• Consistency in timing helps maintain steady therapeutic exposure
• Allow at least 4-6 hours before any activity requiring alertness

Relation to meals:

• Empty stomach absorption is more predictable and generally produces higher peak levels
• Take at least 2 hours after eating or 30 minutes before eating
• High-fat meals can significantly delay and alter absorption
• Some patients tolerate the drug better with a light snack to reduce nausea

What Happens When You Miss a Dose

Missed doses are common in maintenance therapy:

• Single missed dose: Take the next scheduled dose as normal; do not double up
• Multiple missed doses (more than a week): Some clinicians recommend a brief re-titration period, particularly at higher doses
• Extended treatment gaps (more than 2-3 weeks): Loss of dissociative tolerance may occur; restarting at a lower dose and titrating back up is often advisable
• Missing doses does not typically cause withdrawal symptoms, but depression or pain symptoms may return

Dose Adjustment Triggers

Consider dose adjustment when:

Increase dose if:

• No clinical response after 2+ weeks at current dose
• Response is partial but clinically insufficient
• No significant side effects at current dose

Decrease dose if:

• Side effects are intolerable (excessive dissociation, severe nausea, cognitive impairment)
• Response is adequate at a lower dose
• Urinary symptoms develop (urgency, frequency, pain)
• Blood pressure elevations are concerning

Change frequency rather than dose if:

• Good response per session but effects wear off too quickly
• Side effects are dose-related but not severe
• Transitioning from acute to maintenance phase

Individual Variation

Why Dosing Is So Variable Between Patients

The 5-fold or greater variation in effective doses between patients is explained by multiple factors:

Metabolic variation: CYP3A4 and CYP2B6 enzyme activity varies substantially between individuals. Poor metabolizers may need lower doses; ultra-rapid metabolizers may need higher doses.

Body composition: Ketamine is lipophilic and distributes into fat tissue. Patients with higher body fat percentages may have altered drug distribution and duration.

Genetic factors: Pharmacogenomic differences affect receptor sensitivity, enzyme activity, and drug transport. Research is beginning to identify specific genetic variants that predict ketamine response.

Disease severity: More severe depression or pain may require higher doses for meaningful relief.

Prior exposure: Patients with prior ketamine or dissociative experience may have altered receptor sensitivity.

Concurrent medications: Drugs that induce or inhibit CYP enzymes alter ketamine metabolism and may require dose adjustment.

Age: Elderly patients typically have reduced hepatic function and may require lower doses.

The Role of Pharmacogenomics

Pharmacogenomic testing — genetic testing that identifies enzyme variants — can theoretically guide dosing decisions:

• CYP3A4 poor metabolizers: May have higher bioavailability and require lower doses
• CYP2B6 variants: May affect the norketamine-to-ketamine ratio
• GRIN2A/GRIN2B variants: NMDA receptor subunit genes that may affect ketamine sensitivity

Currently, pharmacogenomic testing for ketamine is not standard practice, but it may become more common as the evidence base develops.

Special Populations

Elderly Patients

• Start at 50-75% of the standard starting dose
• Titrate more slowly (3-4 weeks between adjustments)
• Monitor blood pressure closely (elderly patients are more susceptible to hypertensive effects)
• Cognitive side effects may be more pronounced; use lower target doses
• Fall risk during dosing sessions requires appropriate precautions

Patients with Hepatic Impairment

• Reduced first-pass metabolism means higher bioavailability at any given dose
• Start at 50% of the standard dose
• Monitor liver function tests more frequently
• Severe hepatic impairment may contraindicate use

Patients on Opioids

• Concurrent use is common, particularly in pain patients
• Additive sedation and respiratory depression risk (theoretical at therapeutic doses)
• Some evidence suggests ketamine may be opioid-sparing — allowing dose reduction of concurrent opioids
• Start ketamine at standard doses; monitor for excessive sedation

Patients Transitioning from IV to Oral

• Common scenario: stable on IV ketamine, transitioning to oral maintenance
• General conversion: oral dose of 3-6x the IV dose (accounting for bioavailability difference)
• Example: patient stable on 0.5 mg/kg IV may start at 1.5-3.0 mg/kg oral
• Allow an overlap period where both routes are used during transition
• Expect some difference in subjective experience due to pharmacokinetic differences

Dose-Response Relationship

The U-Shaped Curve

Some clinicians and researchers observe a U-shaped dose-response relationship for ketamine's antidepressant effect:

• Very low doses may be insufficient to trigger the glutamatergic cascade
• Moderate doses produce optimal antidepressant response
• Very high doses may produce excessive dissociation that interferes with the therapeutic process

This observation is not universally accepted, and the evidence is primarily clinical rather than from controlled dose-finding studies. However, it supports the principle of finding the minimum effective dose rather than simply escalating until side effects become limiting.

Sub-Dissociative Dosing

A growing area of interest is whether sub-dissociative doses (doses low enough to avoid perceptible dissociation) are therapeutically effective:

• Some evidence suggests that even sub-dissociative doses activate the glutamatergic mechanisms relevant to antidepressant effects
• This would allow dosing that is functionally invisible — no subjective drug experience at all
• Current evidence is mixed; some studies find benefit, others do not
• Most clinical protocols still target at least mild dissociative effects as a proxy for adequate dosing

Maximizing Dose Efficiency

Strategies to get the most therapeutic effect from each dose:

• Consistent timing: Same time of day, same relation to meals
• Appropriate environment: Quiet, comfortable, safe setting during dosing
• Mindful engagement: Some protocols encourage introspective attention during the ketamine experience rather than distraction
• Psychotherapy integration: Scheduling therapy sessions 1-2 days after ketamine dosing may enhance therapeutic benefit
• Sleep hygiene: Adequate sleep improves treatment response across psychiatric conditions

Documentation and Tracking

For Patients

Maintaining a dosing journal is valuable:

• Record each dose: date, time, amount, whether taken with food
• Note side effects and their severity (0-10 scale)
• Rate mood/pain daily using a simple scale
• Track sleep quality and duration
• Note any unusual experiences or concerns
• Bring the journal to prescriber appointments

For Clinicians

Clinical documentation should include:

• Current dose, frequency, and route
• Standardized outcome measures at each visit
• Side effect assessment
• Blood pressure measurements
• Liver function and urinalysis results
• Clinical decision rationale for dose changes
• Assessment of appropriate use and compliance

When Dosing Is Not Working

Defining Treatment Failure

A true non-response to ketamine tablets is defined as:

• No meaningful improvement in target symptoms
• After an adequate trial of at least 4-6 weeks
• At doses of at least 1.5-2.0 mg/kg (for depression)
• With consistent adherence to the dosing protocol
• Without confounding factors (active substance use, medication interactions, major life stressors)

Before Declaring Failure

Consider these possibilities:

1. Insufficient dose: Has the dose been titrated to the upper therapeutic range?
2. Insufficient duration: Some patients respond slowly; 6-8 weeks may be needed
3. Absorption issues: Are meals interfering? Is GI pathology present?
4. Metabolic issues: Ultra-rapid metabolizer status may require higher doses
5. Adherence: Is the patient actually taking doses as prescribed?
6. Formulation: Switching from tablets to troches (or vice versa) may alter absorption
7. Concurrent factors: Untreated sleep apnea, active substance use, or ongoing severe stress can blunt treatment response

Next Steps After Non-Response

If ketamine tablets are genuinely ineffective:

• Consider IV ketamine trial (different pharmacokinetic profile)
• Evaluate for other emerging treatments
• Re-assess the diagnosis
• Optimize other aspects of the treatment plan (psychotherapy, lifestyle, other medications)
• Document the trial and outcome for future reference

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• Mayo Clinic: Treatment-Resistant Depression — Mayo Clinic resource on treatment-resistant depression diagnosis, management, and emerging therapies